Cargando…
In Vitro and In Vivo Evaluation of a (18)F-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging
Expression of the gastrin-releasing peptide receptor (GRPR) in prostate cancer suggests that this receptor can be used as a potential molecular target to visualize and treat these tumors. We have previously investigated an antagonist analog of bombesin (D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH(2), R...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849266/ https://www.ncbi.nlm.nih.gov/pubmed/24312607 http://dx.doi.org/10.1371/journal.pone.0081932 |
_version_ | 1782293898951917568 |
---|---|
author | Varasteh, Zohreh Åberg, Ola Velikyan, Irina Lindeberg, Gunnar Sörensen, Jens Larhed, Mats Antoni, Gunnar Sandström, Mattias Tolmachev, Vladimir Orlova, Anna |
author_facet | Varasteh, Zohreh Åberg, Ola Velikyan, Irina Lindeberg, Gunnar Sörensen, Jens Larhed, Mats Antoni, Gunnar Sandström, Mattias Tolmachev, Vladimir Orlova, Anna |
author_sort | Varasteh, Zohreh |
collection | PubMed |
description | Expression of the gastrin-releasing peptide receptor (GRPR) in prostate cancer suggests that this receptor can be used as a potential molecular target to visualize and treat these tumors. We have previously investigated an antagonist analog of bombesin (D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH(2), RM26) conjugated to 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA) via a diethylene glycol (PEG(2)) spacer (NOTA-P2-RM26) labeled with (68)Ga and (111)In. We found that this conjugate has favorable properties for in vivo imaging of GRPR-expression. The focus of this study was to develop a (18)F-labelled PET agent to visualize GRPR. NOTA-P2-RM26 was labeled with (18)F using aluminum-fluoride chelation. Stability, in vitro binding specificity and cellular processing tests were performed. The inhibition efficiency (IC(50)) of the [(nat)F]AlF-NOTA-P2-RM26 was compared to that of the (nat)Ga-loaded peptide using (125)I-Tyr(4)-BBN as the displacement radioligand. The pharmacokinetics and in vivo binding specificity of the compound were studied. NOTA-P2-RM26 was labeled with (18)F within 1 h (60-65% decay corrected radiochemical yield, 55 GBq/µmol). The radiopeptide was stable in murine serum and showed high specific binding to PC-3 cells. [(nat)F]AlF-NOTA-P2-RM26 showed a low nanomolar inhibition efficiency (IC(50)=4.4±0.8 nM). The internalization rate of the tracer was low. Less than 14% of the cell-bound radioactivity was internalized after 4 h. The biodistribution of [(18)F]AlF-NOTA-P2-RM26 demonstrated rapid blood clearance, low liver uptake and low kidney retention. The tumor uptake at 3 h p.i. was 5.5±0.7 %ID/g, and the tumor-to-blood, -muscle and -bone ratios were 87±42, 159±47, 38±16, respectively. The uptake in tumors, pancreas and other GRPR-expressing organs was significantly reduced when excess amount of non-labeled peptide was co-injected. The low uptake in bone suggests a high in vivo stability of the Al-F bond. High contrast PET image was obtained 3 h p.i. The initial biological results suggest that [(18)F]AlF-NOTA-P2-RM26 is a promising candidate for PET imaging of GRPR in vivo. |
format | Online Article Text |
id | pubmed-3849266 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-38492662013-12-05 In Vitro and In Vivo Evaluation of a (18)F-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging Varasteh, Zohreh Åberg, Ola Velikyan, Irina Lindeberg, Gunnar Sörensen, Jens Larhed, Mats Antoni, Gunnar Sandström, Mattias Tolmachev, Vladimir Orlova, Anna PLoS One Research Article Expression of the gastrin-releasing peptide receptor (GRPR) in prostate cancer suggests that this receptor can be used as a potential molecular target to visualize and treat these tumors. We have previously investigated an antagonist analog of bombesin (D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH(2), RM26) conjugated to 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA) via a diethylene glycol (PEG(2)) spacer (NOTA-P2-RM26) labeled with (68)Ga and (111)In. We found that this conjugate has favorable properties for in vivo imaging of GRPR-expression. The focus of this study was to develop a (18)F-labelled PET agent to visualize GRPR. NOTA-P2-RM26 was labeled with (18)F using aluminum-fluoride chelation. Stability, in vitro binding specificity and cellular processing tests were performed. The inhibition efficiency (IC(50)) of the [(nat)F]AlF-NOTA-P2-RM26 was compared to that of the (nat)Ga-loaded peptide using (125)I-Tyr(4)-BBN as the displacement radioligand. The pharmacokinetics and in vivo binding specificity of the compound were studied. NOTA-P2-RM26 was labeled with (18)F within 1 h (60-65% decay corrected radiochemical yield, 55 GBq/µmol). The radiopeptide was stable in murine serum and showed high specific binding to PC-3 cells. [(nat)F]AlF-NOTA-P2-RM26 showed a low nanomolar inhibition efficiency (IC(50)=4.4±0.8 nM). The internalization rate of the tracer was low. Less than 14% of the cell-bound radioactivity was internalized after 4 h. The biodistribution of [(18)F]AlF-NOTA-P2-RM26 demonstrated rapid blood clearance, low liver uptake and low kidney retention. The tumor uptake at 3 h p.i. was 5.5±0.7 %ID/g, and the tumor-to-blood, -muscle and -bone ratios were 87±42, 159±47, 38±16, respectively. The uptake in tumors, pancreas and other GRPR-expressing organs was significantly reduced when excess amount of non-labeled peptide was co-injected. The low uptake in bone suggests a high in vivo stability of the Al-F bond. High contrast PET image was obtained 3 h p.i. The initial biological results suggest that [(18)F]AlF-NOTA-P2-RM26 is a promising candidate for PET imaging of GRPR in vivo. Public Library of Science 2013-12-03 /pmc/articles/PMC3849266/ /pubmed/24312607 http://dx.doi.org/10.1371/journal.pone.0081932 Text en © 2013 Varasteh et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Varasteh, Zohreh Åberg, Ola Velikyan, Irina Lindeberg, Gunnar Sörensen, Jens Larhed, Mats Antoni, Gunnar Sandström, Mattias Tolmachev, Vladimir Orlova, Anna In Vitro and In Vivo Evaluation of a (18)F-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging |
title | In Vitro and In Vivo Evaluation of a (18)F-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging |
title_full | In Vitro and In Vivo Evaluation of a (18)F-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging |
title_fullStr | In Vitro and In Vivo Evaluation of a (18)F-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging |
title_full_unstemmed | In Vitro and In Vivo Evaluation of a (18)F-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging |
title_short | In Vitro and In Vivo Evaluation of a (18)F-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging |
title_sort | in vitro and in vivo evaluation of a (18)f-labeled high affinity nota conjugated bombesin antagonist as a pet ligand for grpr-targeted tumor imaging |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849266/ https://www.ncbi.nlm.nih.gov/pubmed/24312607 http://dx.doi.org/10.1371/journal.pone.0081932 |
work_keys_str_mv | AT varastehzohreh invitroandinvivoevaluationofa18flabeledhighaffinitynotaconjugatedbombesinantagonistasapetligandforgrprtargetedtumorimaging AT abergola invitroandinvivoevaluationofa18flabeledhighaffinitynotaconjugatedbombesinantagonistasapetligandforgrprtargetedtumorimaging AT velikyanirina invitroandinvivoevaluationofa18flabeledhighaffinitynotaconjugatedbombesinantagonistasapetligandforgrprtargetedtumorimaging AT lindeberggunnar invitroandinvivoevaluationofa18flabeledhighaffinitynotaconjugatedbombesinantagonistasapetligandforgrprtargetedtumorimaging AT sorensenjens invitroandinvivoevaluationofa18flabeledhighaffinitynotaconjugatedbombesinantagonistasapetligandforgrprtargetedtumorimaging AT larhedmats invitroandinvivoevaluationofa18flabeledhighaffinitynotaconjugatedbombesinantagonistasapetligandforgrprtargetedtumorimaging AT antonigunnar invitroandinvivoevaluationofa18flabeledhighaffinitynotaconjugatedbombesinantagonistasapetligandforgrprtargetedtumorimaging AT sandstrommattias invitroandinvivoevaluationofa18flabeledhighaffinitynotaconjugatedbombesinantagonistasapetligandforgrprtargetedtumorimaging AT tolmachevvladimir invitroandinvivoevaluationofa18flabeledhighaffinitynotaconjugatedbombesinantagonistasapetligandforgrprtargetedtumorimaging AT orlovaanna invitroandinvivoevaluationofa18flabeledhighaffinitynotaconjugatedbombesinantagonistasapetligandforgrprtargetedtumorimaging |